Active, not recruitingPhase 3NCT03837483
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
Studying Wiskott-Aldrich syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Telethon
- Intervention
- OTL-103(genetic)
- Enrollment
- 10 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2019 – 2024
Study locations (2)
- Children's Healthcare of Atlanta, Inc, Atlanta, Georgia, United States
- Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET), Milan, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03837483 on ClinicalTrials.govOther trials for Wiskott-Aldrich syndrome
Additional recruiting or active studies for the same condition.